Official Title
A Prospective Analysis of the Quality and Quantity of Antibiotic Prescriptions for Bacterial Respiratory Tract Superinfection in Patients Hospitalized in COVID-19 Wards of a Tertiary University Hospital During the COVID-19 Pandemic
Brief Summary

In this prospective observational study, a quantitative and qualitative analysis of antibiotic prescriptions for presumed respiratory tract (super)infection in patients hospitalized on COVID-19 wards will be made. Drivers of antibiotic prescription for presumed respiratory tract infection in patients suspected of being infected with COVID-19 or with definite COVID-19 infections will be identified.

Detailed Description

Patients hospitalized on a COVID-19 ward for more than 24 hours will be included. Those with
one or more antimicrobial prescription(s) for a presumed respiratory tract (super)infection
will be identified and every antibiotic dose will be scored as appropriate, inappropriate,
suboptimal or unnecessary by at least two infectious disease (ID) specialists, on an
independent manner. If the scoring of the two ID specialists will defer, a third ID
specialist will come to a conclusion after discussion with the two other ID specialists.

A quantification of the total amount of antibiotics, prescribed for presumed respiratory
tract (super)infection will be made for patients with a COVID-19 diagnosis, but also a
quantification for every category of appropriateness will be made.

Possible drivers like the degree of hypoxemia, laboratory parameters, qSOFA score, duration
of symptoms, age, comorbidities, symptoms,... associated with the prescription of
antimicrobials for a presumed respiratory tract (sur)infection will be identified.

Unknown status
SARS-CoV Infection
Antimicrobial Stewardship
Respiratory Tract Infections
Antibiotic Resistance
Eligibility Criteria

Inclusion Criteria:

- Men and women hospitalized in one of the COVID wards (no data will be collected during
a stay on the ICU department) of UZ Brussel for more than 24 hours and willing to sign
the informed consent form (or signed by one of their legal representative(s) if
unable).

Exclusion Criteria:

- patients younger than 18 years old

- patients not willing to sign the informed consent form

- patients hospitalized for a shorter duration than 24 hours on a COVID-19 ward

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Belgium
Locations

UZ Brussel
Brussel, Belgium

Investigator: Dora Mss Monteyne, nurse
Contact: +3224776001
dora.monteyne@uzbrussel.be

Contacts

Johan Dr Van Laethem, MD
+3224779517 - +322
johan.vanlaethem@uzbrussel.be

Johan Dr Van Laethem, MD, Principal Investigator
Principal Investigator

Universitair Ziekenhuis Brussel
NCT Number
Keywords
respiratory tract infection
antimicrobial stewardship
SARS-CoV Infection
Covid-19
Antibiotic resistance
MeSH Terms
Infections
Communicable Diseases
COVID-19
Respiratory Tract Infections
Severe Acute Respiratory Syndrome
Superinfection